Neurology

Treatment with ST266 linked to increased survival of retinal ganglion cells in patients with multiple sclerosis.

Female first-degree relatives face the highest risk of developing multiple sclerosis.

MicroRNAs could monitor the severity of MS in the future.

Ocrelizumab may effectively treat patients with relapsing multiple sclerosis and primary progressive multiple sclerosis.

Top articles of the week from Specialty Pharmacy Times.

Repetitive transcranial magnet stimulation shows promise treating symptoms of MS.

Working memory was improved in patients with MS who underwent repetitive transcranial magnetic stimulation.

Teva loses patent infringement litigations for Copaxone.

Ocrelizumab reduced disease activity in patients with relapsing multiple sclerosis and primary progressive multiple sclerosis.

Dalfampridine extended-release tablets deemed bioequivalent of Amprya.

Dalfampridine extended-release tablets is the bioequivalent of Amprya.

Conflicting evidence surrounds the association between multiple sclerosis and uveitis.

The FDA has given final approval to Aurobindo Pharma Limited for dalfampridine extended-release tablets (10 mg).

No evidence of disease activity criteria in multiple sclerosis may need to be reconsidered.

Without a special license, researchers can only conduct observational studies that include cannabis.

High-risk family members more likely to have early subclinical manifestations of MS.

Rituximab found to be safe and effective in patients with primary progressive MS.

Providers need to monitor lack of physical activity and poor diet among patients with multiple sclerosis.

Majority of patients do not adhere to dietary guidelines set by the US Department of Agriculture.

Symptoms significantly worsened in patients treated with MS drug alemtuzumab.

Top news of the day from across the health care landscape.

Improved treatment options for patients with relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis.

Investigators identify factors that contribute to the chronic nature of autoimmune diseases.

Top news of the day from across the health care landscape.

A 30% increase in hemoglobin caused the brain to shrink in patients with multiple sclerosis by 0.1%.